Application and use method of combined ELISA (enzyme-linked immuno sorbent assay) kit
The detection of SASP classic factors through a combined ELISA kit solves the problem that the existing technology is difficult to monitor aging-related factors in human peripheral blood, and realizes accurate assessment of the degree of aging and monitoring of organ health status, which has important clinical application value.
Patent Information
- Application Number
- CN202410964791.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-26
AI Technical Summary
Existing detection methods are difficult to effectively monitor and evaluate the classic SASP factors related to aging in human peripheral blood, resulting in insufficient understanding of the aging mechanism of human organs, which in turn affects the diagnosis and prevention of chronic diseases.
A combined ELISA kit was developed, including microplate, buffer, blocking solution, sample dilution, enzyme dilution, SASP factor standards and specific polyclonal antibodies, to detect SASP classic factors through specific steps and methods. , ensuring high sensitivity and high specificity.
Quantitative detection of SASP classic factors is realized, non-invasive, direct and effective methods are provided, and can non-invasively evaluate the health status of the organ and the aging level of human body, improve the accuracy and reliability of the detection, and has clinical application value.
Smart Images

Figure CN119023970A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunoassay analysis, and in particular to a combined ELISA kit for quantitatively detecting SASP classical factors in human peripheral blood and a use method thereof. Background Art
[0002] Chronological aging leads to universal degenerative changes in the structure and function of various parts of the body, which significantly increases the risk of the body suffering from various chronic diseases in old age. Over the years, comprehensive studies using mice and other model organisms have revealed the molecular changes that occur across multiple organs during the aging process, and have identified unique aging trajectories and corresponding time nodes. Some specific organs, such as the brain, heart, lungs, liver, and kidneys, have significant differences in susceptibility and resistance to age-related diseases among people. However, little is known about how human organs change with age at the molecular level. Understanding the aging of human organs at the molecular level is crucial to addressing the increasing number of aging diseases worldwide and the social and medical burden they cause, and has the potential to revolutionize the model of patient care, preventive medicine, and drug development, as well as the paradigm of medical intervention under clinical conditions.
[0003] Cellular senescence is an essentially irreversible state of cell cycle arrest, which was originally considered to be a tumor suppressor program that promotes tissue homeostasis by identifying damaged cells for immune-mediated clearance. The senescence-associated secretory phenotype (SASP) is a typical feature of senescent cells, which can lead to chronic inflammation in a variety of tissues and organs, the extent of which usually depends on the specific microenvironmental composition and pathophysiological properties of the senescent cells. SASP classical factors refer to a series of specific, key, and representative molecules secreted by senescent cells during the process of cell senescence. These factors have multiple functions, including effects on surrounding cells, promoting inflammatory responses, and affecting tissue repair and regeneration.
[0004] The most widely used method for detecting human blood markers in the current medical and health field is the enzyme-linked immunosorbent assay (ELISA). The development of diagnostic technology that can be used to monitor the circulating state of SASP factors in human peripheral blood, especially high-sensitivity, high-specificity and high-selectivity ELISA kits, is a means of aging assessment that fully utilizes the international frontier of SASP research and promotes the use of serum from elderly individuals or patients with age-related diseases as clinical detection targets, which is of great significance. Summary of the invention
[0005] In order to solve the problems existing in the background technology, the present invention provides a combined ELISA kit for use as a positive control or a negative control. The combined ELISA kit is pre-packaged with a microplate, a buffer, a blocking solution, a sample diluent, an enzyme diluent, a SASP factor standard, a SASP classical factor antibody, a SASP classical factor antibody labeled with a biological enzyme, and a luminescent substrate, wherein the SASP classical factor antibody is a specific polyclonal antibody of the SASP classical exocrine factor of human cells.
[0006] The method for using the combined ELISA kit for positive control or negative control comprises the following steps:
[0007] S1. Coating the microplate: Mix the SASP classical exocrine factor antibody of the combined ELISA kit with the buffer, add it to the microplate for coating, and then block the microplate with a blocking solution to form a coated plate;
[0008] S2. Preparation of standards and samples: mixing the SASP classical exocrine factor standard with the sample diluent to prepare an antigen standard; at the same time, mixing the clinical blood supernatant to be tested with the sample diluent to prepare a test solution;
[0009] S3, incubation and incubation: adding the test solution, antigen standard and SASP classical exocrine factor antibody solution labeled with biological enzyme to the coated plate for incubation, and finally adding the luminescent substrate for incubation;
[0010] S4, luminescence value detection: Detect the luminescence value of each well by a luminometer;
[0011] S5. Data analysis: Calculate the content of SASP classical exocrine factors in the sample to be tested according to the standard curve;
[0012] S6. Use of controls: Add samples known to contain the target SASP classical factor to the experiment to verify the detection ability of the kit; the positive control produces a signal to confirm that the experimental system can detect the target molecule; or:
[0013] Use sample dilutions without the target SASP classical factor as a negative control to ensure that there is no nonspecific binding or background signal in the experiment.
[0014] The combined ELISA kit is used for detecting the content of SASP classical exocrine factors in samples. The combined ELISA kit is pre-packaged with a microplate, a buffer, a blocking solution, a sample diluent, an enzyme diluent, a SASP factor standard, a SASP classical factor antibody, a biological enzyme-labeled SASP classical factor antibody, and a luminescent substrate, wherein the SASP classical factor antibody is a specific polyclonal antibody of the SASP classical exocrine factors of human cells.
[0015] The combined ELISA kit is used for detecting the content of SASP classical exocrine factors in a sample, characterized in that the preparation process of the SASP classical factor antibody comprises:
[0016] Step 1: Molecularly clone eight human SASP classical factors IL1a, IL1b, IL6, IL8, MMP1, MMP3, GM-CSF, and SPINK1 into the pET-28 fusion protein prokaryotic expression vector (5369 bp);
[0017] Step 2: Design primers based on the T7 promoter sequence, sequence to determine the MCS segment gene ID, and sequentially transfer the vector into the BL21DE3 competent Escherichia coli strain;
[0018] Step 3: After inducing the strain to express each target protein, high-purity recombinant protein with a His tag at the N-terminus is obtained by affinity chromatography;
[0019] Step 4: New Zealand white rabbits are injected with purified proteins in sequence for immunization, and titer detection is performed; samples include pre-immunization negative blood control, first immunization, second immunization, third immunization and fourth immunization gradient titer detection, and the titer detection data are analyzed; the immunization cycle is 2 months;
[0020] Step 5: Animal serum collection and antibody purification in small amounts; after immunization, serum collection takes place over a 7-12 day period, in batches according to the immunization time; the volume of whole blood collected from each rabbit is no less than 50 ml, and the volume of serum is no less than 30 ml;
[0021] Step 6: Column purification of polyclonal antibodies: first take a small amount of antibody for purification and identification, and determine the basic purity based on the SDS-PAGE gel image.
[0022] The method for using the combined ELISA kit to detect the content of SASP classical exocrine factors in a sample comprises the following steps:
[0023] P1. Mix the SASP classical exocrine factor antibodies with the buffer solution one by one, add the obtained antibody solution to the microplate for coating, and then add the blocking solution to the microplate for blocking to obtain a coated plate;
[0024] P2, mixing the sample to be tested with the sample diluent to prepare a test solution and an antigen standard;
[0025] P3, mixing the SASP classical exocrine factor standard with the sample diluent to prepare an antigen standard;
[0026] P4, mixing the SASP classical exocrine factor antibody labeled with biological enzyme with the enzyme diluent to obtain the SASP classical exocrine factor antibody solution labeled with biological enzyme;
[0027] P5, add the test solution and the antigen standard to the coated plate for incubation, then add the SASP classic exocrine factor antibody solution labeled with a biological enzyme for incubation, and finally add the luminescent substrate for incubation;
[0028] P6. Detect the luminescence value and obtain the content of SASP classical exocrine factors in the sample to be tested according to the standard curve.
[0029] The method for using the combined ELISA kit for detecting the content of SASP classical exocrine factors in a sample is characterized in that the coating concentration of the SASP classical exocrine factor antibody is 4-10 μg / mL.
[0030] The method for using the combined ELISA kit for detecting the content of SASP classical exocrine factors in a sample is characterized in that, in the biological enzyme-labeled SASP classical exocrine factor antibody solution, the volume ratio of the biological enzyme-labeled SASP classical exocrine factor antibody to the enzyme diluent is 1:(2500-3500)
[0031] The preparation process of the SASP classical factor antibody of the present invention comprises:
[0032] Step 1: Molecular cloning of 8 human SASP classical factors IL1a, IL1b, IL6, IL8, MMP1, MMP3, GM-CSF, SPINK1 in pET-28 fusion protein prokaryotic expression vector (5369bp size); Molecular cloning is a biotechnology method used to replicate specific DNA fragments in vitro and insert them into vectors for replication or expression in organisms (such as bacteria, yeast or mammalian cells). SASP factors are a group of proteins and other molecules released by aging cells that can affect the cell microenvironment and have important effects on cell fate, tissue homeostasis and disease development. These eight factors are: IL1a (interleukin 1α), IL1b (interleukin 1β), IL6 (interleukin 6), IL8 (interleukin 8), MMP1 (matrix metalloproteinase 1), MMP3 (matrix metalloproteinase 3), GM-CSF (granulocyte-macrophage colony stimulating factor), and SPINK1 (trypsin inhibitor 1).
[0033] pET-28 fusion protein prokaryotic expression vector: pET-28 is a plasmid vector used to express recombinant proteins in prokaryotes such as Escherichia coli. Fusion protein prokaryotic expression vector means that the vector is designed to express fusion protein, that is, the target protein is fused with a tag or domain (such as affinity tag) for subsequent purification or detection. "5369bp" indicates the linear size or length of this vector, that is, it contains 5369 base pairs.
[0034] Step 2: Design primers based on the T7 promoter sequence, sequence to determine the MCS segment gene ID, and sequentially transform the vector into the BL21 competent E. coli strain; Design primers based on the T7 promoter sequence:
[0035] The T7 promoter is a commonly used strong promoter that is often used to efficiently express foreign genes in E. coli. Primers are usually designed to amplify specific DNA fragments through PCR (polymerase chain reaction). In this case, the primers are designed based on the T7 promoter sequence, with the purpose of amplifying a DNA fragment containing the promoter, so that the T7 promoter can be used to drive the efficient expression of the target gene in the subsequent transformation and expression process.
[0036] Sequencing to determine the MCS segment gene ID:
[0037] MCS (Multiple Cloning Site) is a region on the vector that contains multiple different restriction enzyme sites for inserting foreign DNA fragments. Dideoxy end termination sequencing is a method to determine the sequence of the DNA fragment inserted in the MCS segment, so that the corresponding ID (identity or identifier of the gene) of the inserted gene can be determined. This helps to verify whether the inserted DNA fragment is correct and determine the protein information it encodes.
[0038] The vectors were sequentially transformed into BL21 competent E. coli strains:
[0039] BL21 is a commonly used E. coli strain, often used to express genes driven by the T7 promoter. Competent cells are cells that have been specially treated to easily absorb and integrate foreign DNA. Transferring a vector (usually a plasmid) into BL21 competent cells means introducing a plasmid containing a target gene into E. coli so that the target protein can be expressed in the cell.
[0040] Step 3: After inducing the strain to express each target protein, high-purity recombinant protein (N-terminal His tag) was obtained by affinity chromatography; the initial yield of each protein after purification was 5 mg; Inducing the strain to express each target protein:
[0041] After the plasmid containing the target gene is transferred into BL21 E. coli, specific conditions (such as adding the inducer IPTG) are required to induce the expression of the target protein. This is because the T7 promoter is usually activated under specific conditions (such as IPTG induction), thereby driving the transcription and translation of the target gene to produce the target protein.
[0042] Obtain high-purity recombinant protein with a His tag at the N-terminus by affinity chromatography:
[0043] Affinity chromatography is a method for separation and purification based on the high affinity between proteins and specific ligands. In this step, the interaction between the His tag at the N-terminus of the recombinant protein and the metal ions on the affinity chromatography column is utilized. When the solution containing the recombinant protein flows through the chromatography column, the protein with the His tag will bind to the metal ions, while other impurities are eluted because they cannot bind to the metal ions or bind weakly. Subsequently, by setting the elution conditions (such as determining a certain range of eluent pH and / or ionic strength), the recombinant protein bound to the metal ions can be eluted, thereby obtaining a high-purity recombinant protein that meets the requirements of biochemical experiments or practical applications.
[0044] Step 4: New Zealand white rabbits are injected with purified proteins in sequence for immunization, and titer detection is performed; samples include pre-immunization negative blood control, first immunization, second immunization, third immunization and fourth immunization gradient titer detection, and the titer detection data are analyzed; the immunization cycle is 2 months;
[0045] Step 5: Animal serum collection and antibody purification in small amounts; after immunization, serum collection takes place over a 7-12 day period, in batches according to the immunization time; the volume of whole blood collected from each rabbit is no less than 50 ml, and the volume of serum is no less than 30 ml;
[0046] Step 6: Column purification of polyclonal antibodies: first take a small amount of antibody for purification and identification, and determine the basic purity based on the SDS-PAGE gel image. Each batch of purification provides a corresponding gel image for reference.
[0047] Column purification: "Column" usually refers to purification using a chromatography column. The chromatography column is filled with specific materials (such as gels, resins, etc.) that can interact with different components in the mixture in different ways, thereby achieving separation.
[0048] In antibody purification, the selection of chromatography columns and operating conditions are determined based on the characteristics of the antibody and the required purity. When the antibody solution passes through the chromatography column, impurities that bind weakly to the target antibody will be eluted first, while the target antibody will be collected in subsequent steps by changing the elution conditions.
[0049] Purification qualification: Before large-scale purification, a small amount of antibody is usually taken for purification qualification. This is to evaluate the effectiveness of the purification conditions and ensure that the final purification results meet expectations.
[0050] There are many methods for purification and identification, but SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) is a commonly used method. Through SDS-PAGE, the separation of antibodies on the gel can be observed, thereby preliminarily judging their purity.
[0051] SDS-PAGE gel analysis: SDS-PAGE gel is an intuitive way to show the purity of the antibody. In the gel, proteins of different molecular weights will form different bands. The band of the target antibody should be clear, single, and consistent with the expected molecular weight.
[0052] By analyzing the gel image, you can determine whether the purity of the antibody meets the requirements. If there are multiple bands or the target band is not clear on the gel image, it may mean that the purity of the antibody is not high enough and the purification conditions need to be further adjusted.
[0053] Each batch of purification provides a corresponding gel image for reference: In order to ensure that each batch of purified antibodies has a consistent high purity, SDS-PAGE analysis is usually performed after each purification, and a corresponding gel image is provided as a reference. The purpose of this is to facilitate tracking and comparing the purity of different batches of antibodies and ensure the stability and consistency of product quality.
[0054] The beneficial effects achieved by the present invention are:
[0055] First, the detection process of the present invention is a direct and effective non-invasive method, which can detect aging-related proteins or metabolites to determine the aging load in the blood, can assist in future large-scale plasma proteomics and machine learning, and can be used to non-invasively measure the health status of organs and the degree of human aging. The present invention uses a series of organ-specific proteins and fibrins, or protein molecules closely related to physiological age, to evaluate and monitor individuals. This technology has the potential to promote the combination of clinical diagnosis and intervention strategies in aging medicine in the future, thereby achieving the deconvolution of the aging rates of different organs within an individual, thereby achieving monitoring and evaluation of aging in terms of organ-level resolution. Finally, through the determination of luminescence values and the application of standard curves, the content of SASP classical factors in the sample can be accurately calculated, providing quantitative data for aging assessment.
[0056] Second, the accuracy of the experiment is improved by using positive and negative control substances in the present invention, which not only verifies the performance of the experimental operation and the kit, but also ensures the accuracy of the experimental results. At the same time, the use of control substances enhances the reliability of the experiment and helps to identify errors that may occur during the experiment, such as cross-contamination or operational errors. In addition, by adding a certain concentration of SASP classical factor antibodies as neutralizing antibodies to the sample diluent, the detection range is expanded, so that the level of SASP classical factors in the sample can be more comprehensively evaluated. The direct and effective non-invasive detection method provided by this ELISA kit is particularly suitable for rapid detection under clinical conditions. In terms of clinical application, this technology can monitor SASP factors in human peripheral blood, which has important potential value for assessing the degree of aging. In addition, quantitative detection of SASP classical factors helps to promote the development of intervention strategies in the field of aging medicine.
[0057] Third, in the preparation process of SASP classical factor antibodies, specific polyclonal antibodies of human cell SASP classical exocrine factors were used for specific identification, ensuring accurate detection of target SASP factors. Then, high-purity recombinant proteins with His tags at the N-terminus were obtained through affinity chromatography technology to ensure the quality and titer of the antibodies. By immunizing New Zealand white rabbits and performing titer testing, it was ensured that the prepared antibodies had high immunoreactivity, which was extremely critical for subsequent ELISA testing. In the antibody purification stage, the purity and quality of the antibodies were further improved by collecting animal serum and purifying a small amount of them, combined with column purification steps. Each batch of purified antibodies was identified by SDS-PAGE gel image to ensure the stability and consistency of product quality. This series of refined operating steps jointly ensures the high specificity, high purity and high stability of SASP classical factor antibodies. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 The linear regression curve fitting result of the luminescence value of the standard sample in comparative example 1;
[0059] Figure 2 This is the linear regression curve fitting result of the luminescence value of the standard sample in Example 1.
[0060] Figure 3 Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-IL1a.
[0061] Figure 4 Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-IL1b.
[0062] Figure 5Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-IL6.
[0063] Figure 6 Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-IL8.
[0064] Figure 7 Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-MMP1.
[0065] Figure 8 Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-MMP3.
[0066] Fig. 9 Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-GM-CSF.
[0067] Fig.10 Molecular cloning step: Base sequence signal diagram after DNA sequencing of pET28-SPINK1. DETAILED DESCRIPTION
[0068] The following will be combined with the accompanying drawings in the present invention to clearly, completely and accurately describe the technical solutions in the present invention. In addition, the forms of the various structures described in the following embodiments are only examples, and the present invention is not limited to the various structures described in the following embodiments. All other embodiments obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.
[0069] Reference Figure 1-Figure 10 The present invention discloses a combined ELISA kit and a method for using the quantitative detection of human peripheral blood SASP classical factors. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0070] English and Chinese:
[0071] ADP: adenosine diphosphate;
[0072] Casein: casein;
[0073] Classical SASP factors: IL1a, IL1b, IL6, IL8, MMP1, MMP3, GM-CSF and SPINK1;
[0074] IL1a is interleukin 1α, IL1b is interleukin 1β, IL6 is interleukin 6, IL8 is interleukin 8, MMP1 is matrix metalloproteinase 1, MMP3 is matrix metalloproteinase 3, GM-CSF is granulocyte-macrophage colony-stimulating factor, and SPINK1 is pancreatic secretory trypsin inhibitor 1;
[0075] PBST: The full English name is phosphate buffered solution, which is phosphate buffered saline containing Tween-20.
[0076] The present invention is applicable to the following instruments:
[0077] Sampler, incubator, plate washer, oscillating mixer, luminometer.
[0078] Sample requirements:
[0079] 1) Please equilibrate the sample at room temperature for more than 30 minutes before use. Frozen samples need to be mixed before the experiment.
[0080] 2) Samples containing suspended fibrin or aggregates or severe hemolysis cannot be tested.
[0081] 3) There should be no microorganisms in the sample. Sterile isolated samples can be stored at 2-8°C for one week. For long-term storage, they should be frozen at low temperatures to avoid repeated freezing and thawing.
[0082] Preparation before the experiment:
[0083] 1) Dissolve 1 pack of solid washing liquid in 500 ml of distilled water and set aside.
[0084] 2) Take out the test kit and the sample to be tested, and restore all reagents and samples to room temperature (18-25°C).
[0085] 3) Adjust the thermostat or water bath to the reaction temperature.
[0086] 4) 30 minutes in advance, mix the luminescent substrate A and B solutions in equal proportions to the required volume for this test.
[0087] The kit of the present invention is stored at 2-8°C and has a shelf life of 6 months. The kit is equilibrated to room temperature (about 30 minutes) before use. The unused microplate must be sealed with a desiccant and its packaging in a ziplock bag and stored at 2-8°C. The liquid reagent is gently shaken and mixed before the experiment, and immediately sealed and stored at 2-8°C after use.
[0088] The kit for quantitatively detecting the SASP classical factors provided by the present invention and the reagents or instruments used in the detection method for clinical diagnosis purposes can all be purchased from the market.
[0089] The present invention provides a combined ELISA kit for quantitatively detecting SASP classical factors in human peripheral blood, which comprises SASP classical factor antibodies, which are specific polyclonal antibodies of SASP classical exocrine factors of human-derived cells. The combined ELISA kit for quantitatively detecting SASP classical factors in human peripheral blood is pre-packaged with a microplate, a buffer, a blocking solution, a sample diluent, an enzyme diluent, a SASP factor standard, a SASP classical factor antibody, a SASP classical factor antibody labeled with a biological enzyme, and a luminescent substrate.
[0090] The enzyme-labeled SASP classical exocrine factor antibody is a horseradish peroxidase-labeled SASP classical exocrine factor antibody. The buffer is a CB buffer with a molar concentration of 0.01-0.1M and a pH value of 90-100. The preservative is ProClin300 TM Antimicrobial.
[0091] The sample diluent contains:
[0092] A SASP classical factor antibody with a mass fraction of 5-15 μg / ml; the SASP classical factor antibody is a polyclonal antibody of any one of the human cell SASP classical exocrine factors IL1a, IL1b, IL6, IL8, MMP1, MMP3, GM-CSF, and SPINK1;
[0093] PBST with a mass fraction of 15-25 mg / ml, wherein the PBST is a phosphate-tween buffer; fetal bovine serum with a volume fraction of 13-17 vt%; a preservative with a volume fraction of 0.08-0.12 vt%; and water to make up the proportion. In a preferred embodiment, the enzyme diluent contains: PBST with a mass fraction of 20 g / l, wherein the PBST is a phosphate-tween buffer; bovine albumin with a mass fraction of 10 g / l; a preservative with a volume fraction of 0.1 vt%; and water to make up the proportion.
[0094] The present invention also provides a combined ELISA kit for quantitatively detecting human peripheral blood SASP classical factors as a positive control substance and / or a negative control substance.
[0095] The method for using the combined ELISA kit for quantitatively detecting SASP classical factors in human peripheral blood comprises the following steps:
[0096] P1. Mix the SASP classical exocrine factor antibodies with the buffer solution one by one, add the obtained antibody solution to the microplate for coating, and then add the blocking solution to the microplate for blocking to obtain a coated plate;
[0097] P2, mixing the sample to be tested with the sample diluent to prepare a test solution and an antigen standard;
[0098] P3, mixing the SASP classical exocrine factor standard with the sample diluent to prepare an antigen standard;
[0099] P4, mixing the SASP classical exocrine factor antibody labeled with biological enzyme with the enzyme diluent to obtain the SASP classical exocrine factor antibody solution labeled with biological enzyme;
[0100] P5, add the test solution and the antigen standard to the coated plate for incubation, then add the SASP classic exocrine factor antibody solution labeled with a biological enzyme for incubation, and finally add the luminescent substrate for incubation;
[0101] P6. Detect the luminescence value and obtain the content of SASP classical exocrine factors in the sample to be tested according to the standard curve.
[0102] The coating concentration of the SASP classical exocrine factor antibody is 4-10 μg / mL. In the biological enzyme-labeled SASP classical exocrine factor antibody solution, the volume ratio of the biological enzyme-labeled SASP classical exocrine factor antibody to the enzyme diluent is 1:(2500-3500).
[0103] The method for using the combined ELISA kit for positive control or negative control comprises the following steps:
[0104] S1. Coating the microplate: Mix the SASP classical exocrine factor antibody of the combined ELISA kit with the buffer, add it to the microplate for coating, and then block the microplate with a blocking solution to form a coated plate;
[0105] S2. Preparation of standards and samples: mixing the SASP classical exocrine factor standard with the sample diluent to prepare an antigen standard; at the same time, mixing the clinical blood supernatant to be tested with the sample diluent to prepare a test solution;
[0106] S3, incubation and incubation: adding the test solution, antigen standard and SASP classical exocrine factor antibody solution labeled with biological enzyme to the coated plate for incubation, and finally adding the luminescent substrate for incubation;
[0107] S4, luminescence value detection: Detect the luminescence value of each well by a luminometer;
[0108] S5. Data analysis: Calculate the content of SASP classical exocrine factors in the sample to be tested according to the standard curve;
[0109] S6. Use of controls: Add samples known to contain the target SASP classical factor to the experiment to verify the detection ability of the kit; the positive control produces a signal to confirm that the experimental system can detect the target molecule; or:
[0110] Use sample dilutions without the target SASP classical factor as a negative control to ensure that there is no nonspecific binding or background signal in the experiment.
[0111] The present invention will be further described below in conjunction with embodiments:
[0112] Example 1 Kit of the present invention and preparation method thereof,
[0113] 1. The components and contents of the kit of the present invention are shown in Tables 1 to 4:
[0114] Table 1. 0.05M, pH 9.6 CB buffer formula:
[0115] Item Name Raw material requirements Standard volume per liter Purified water Homemade, quality inspection passed 1000ml <![CDATA[Na2CO3]]> Analytical grade 1.99g <![CDATA[NaHCO3]]> Analytical grade 2.53g
[0116] Table 2. Blocking solution formula:
[0117] Reagent name Raw material requirements Theoretical weighing amount <![CDATA[NaH2PO4·2H2O]]> Analytical grade 2.25g <![CDATA[Na2HPO4·12H2O]]> Analytical grade 25g NaCl Analytical grade 35g Casein Analytical grade 50g ADP / 5g P300 / 5ml sucrose Analytical grade 500g Purified water Homemade, quality inspection compliant 500ml
[0118] Table 3. Sample dilution formula (pH = 7.4):
[0119] Product Name Raw material requirements Theoretical dosage Purified water Homemade, quality inspection compliant 850ml PBST Quality Inspection Compliance 20g Fetal bovine serum Quality Inspection Compliance 150ml P300 Quality Inspection Compliance 1ml Rabbit anti-human SASP antibody Homemade, quality inspection compliant 5mgl
[0120] Table 4. Enzyme dilution formula (pH = 7.4):
[0121] Product Name Raw material requirements Theoretical dosage Purified water Homemade, quality inspection compliant 1000ml PBST Quality Inspection Compliance 20g Fetal bovine serum Quality Inspection Compliance 10g P300 Quality Inspection Compliance 1ml
[0122] 5. Rabbit anti-human SASP classical factor antibody;
[0123] 6. Antigen standards (SDS-PAGE quantification, purity above 95%);
[0124] 7 Horseradish peroxidase-labeled rabbit anti-human SASP classical factor antibody;
[0125] 8 Luminescent substrate: Yantai Kinolais Biotechnology Co., Ltd.;
[0126] Substrate luminescent solution A (store in dark): luminol, Tris buffer, etc.;
[0127] Substrate luminescent liquid B: hydrogen peroxide, Tris-buffer, etc.;
[0128] 9 Positive control: dilute the standard of recombinant human SASP classical factor antibody with sample diluent containing neutralizing antibody (concentrations are 200μg / mL, 100μg / mL, 50μg / mL, 25g / ml, 1250μg / ml, 6250μg / ml, 31250μg / ml, 1560μg / ml)
[0129] 10 Negative control: sample diluent.
[0130] 2. The corresponding preparation methods of each reagent in the kit of the present invention:
[0131] 1CB buffer preparation procedure
[0132] 1) Determine the volume of coating buffer according to actual needs.
[0133] 2) Calculate the dosage of the above reagents according to the standard formula.
[0134] 3) Add the above reagents one by one in an accurate amount into a container, add the required amount of purified water, stir thoroughly to dissolve. Measure and record the pH value, which can be theoretical pH ± 0.05.
[0135] 4) Complete the preparation one day before the planned coating.
[0136] 5) Store the prepared coating buffer at 2-8°C.
[0137] 2. Blocking solution preparation procedure
[0138] 1) Determine the volume of buffer solution as needed and calculate the amount of various raw materials according to the standard formula.
[0139] 2) Add accurately weighed chemical reagents into the container and add the required amount of purified water.
[0140] 3) After stirring thoroughly to dissolve, divide into packages.
[0141] 4) After preparation, indicate the name, batch number, preparer, preparation date, and amount of liquid prepared, and mark the qualified status. If it needs to be stored for a long time, it must be stored at -20℃.
[0142] 3. Sample dilution preparation process
[0143] 1) Determine the volume of buffer solution as needed and calculate the corresponding amounts of various raw materials according to the standard formula.
[0144] 2) Add the required amount of solid washing solution into the container and add 15% fetal bovine serum.
[0145] 3) Add 1 ml of P300 per liter.
[0146] 4) After fully stirring and dissolving, divide into packages.
[0147] 5) After preparation, indicate the name and batch number. If long-term storage is required, store at -20℃.
[0148] 4. Preparation of rabbit polyclonal antibody against SASP classical factors and horseradish peroxidase (HRP) labeled antibody.
[0149] Animal immunization and rabbit polyclonal antibody preparation: The immunogen and the detection source are both human SASP classical factors, with a purity of more than 95%, from Yantai Kinoles Biotechnology Co., Ltd. The prokaryotic expression recombinant protein purification product of human SASP classical factors is used as the immune antigen.
[0150] Preparation process:
[0151] (1) Molecular cloning of eight human SASP classical factors (IL1a, IL1b, IL6, IL8, MMP1, MMP3, GM-CSF or SPINK1) into the pET-28 fusion protein prokaryotic expression vector (5369 bp in size).
[0152] (2) Using the T7 promoter sequence as a basis, primers were designed and sequenced to determine the MCS segment gene ID ( Figure 3-Figure 10 ), and the vectors were sequentially transformed into BL21 competent Escherichia coli strain.
[0153] (3) After inducing the strain to express each target protein, high-purity recombinant protein (N-terminal His tag) was obtained by affinity chromatography. The initial yield of each protein after purification was 5 mg.
[0154] (4) New Zealand white rabbits were injected with purified proteins for immunization, and titer detection was performed. The samples included negative blood before immunization (control), gradient titer detection of the first immunization, the second immunization, the third immunization, and the fourth immunization, and the titer detection data were analyzed.
[0155] (5) The general immunization cycle is 2 months. If there are special circumstances, booster immunization can be given once at most.
[0156] (6) Collection of animal serum and purification of a small amount of antibodies. After immunization, serum collection takes 7-12 days and is collected in batches according to the immunization time. The volume of whole blood collected from each rabbit is not less than 50 ml, and the volume of serum is not less than 30 ml.
[0157] (7) Column purification of polyclonal antibodies. First, take a small amount of antibody for purification and identification, and determine the basic purity based on the SDS-PAGE gel image. Each batch of purification is provided with a corresponding gel image as a reference.
[0158] (8) The amount of polyclonal antibody prepared is 2 mg antibody / animal. A total of 4 mg is provided in this stage, and 1 mg is obtained in the subsequent stage for the development of high-quality SASP kits.
[0159] (9) Determination of ELISA kit conditions: Use five 96-well plates for each SASP factor protein to determine the conditions.
[0160] (10) 8-wells are arranged vertically to form 12 columns, and each 96-well plate can be arranged with 12 8-wells to form a combined ELISA kit specifically for combined detection of peripheral blood SASP factors under clinical conditions.
[0161] Horseradish peroxidase (HRP) labeled antibodies
[0162] Horseradish peroxidase was dissolved in triple distilled water, activated with sodium periodate solution, and reacted with ethylene glycol. The reaction mixture was placed in a dialysis bag and dialyzed with acetate buffer. The activated horseradish peroxidase was added to the labeled substance (rabbit anti-human SASP classical factor antibody) and mixed evenly. The pH was adjusted to alkaline with carbonate buffer, reacted at 4°C for 20-24h, NaHB4 solution was added, reacted at 4°C for 2h, placed in a dialysis bag, dialyzed with phosphate buffer, and aliquoted and added with a protein protective agent (containing glycerol at a final concentration of 50%), and stored at -20°C for later use.
[0163] 5. Preparation of Antigen Standards
[0164] The SASP classical factor antigen was diluted in the following gradient: 200 μg / ml, 100 μg / ml, 50 μg / ml, 25 g / ml, 12.50 μg / ml, 6.250 μg / ml, 3.1250 μg / ml, 1.560 μg / ml, and the diluent was the sample diluent to prepare the standard.
[0165] Comparative Example 1 Control Kit
[0166] The sample diluent in the control kit is different from that in Example 1, lacking rabbit anti-human SASP classical factor antibody, and the rest is the same as in Example 1. The formula of the sample diluent (pH=7.4) in the control kit is as follows:
[0167] Table 5. Sample diluent (pH = 7.4) formula in the control kit
[0168] Product Name Raw material requirements Theoretical dosage Purified water Homemade, quality inspection compliant 950ml PBST Quality Inspection Compliance 20g Fetal bovine serum Quality Inspection Compliance 150ml P300 Quality Inspection Compliance 1.0ml
[0169] Experimental Example 1. Combined ELISA Detection Method for SASP Classical Factors
[0170] 1 Test materials
[0171] Example 1 kit, Comparative Example 1 kit.
[0172] 2 Test steps
[0173] Coated plate preparation
[0174] 1) Coating. Use 0.05M, pH 9.6 CB buffer to dilute SASP classical factor antibodies (rabbit polyclonal antibodies) to 5μg / ml, cover with plastic wrap, mark the beaker body and place it on a magnetic stirrer, stir for more than 20 minutes, add to the luminescent microplate after oscillation, add 100μl / well, ensure that the liquid covers the bottom of the well, cover the plate sticker, and leave it in a 4℃ refrigerator for overnight coating (12-24 hours);
[0175] 2) Blocking. Shake off the coating solution, wash the plate twice, pat dry with absorbent paper, block with 150 μl / well of Casein blocking solution, and place horizontally in a 4°C refrigerator overnight (12-24 hours);
[0176] 3) Harvest. Shake off the blocking solution, pat dry with absorbent paper, put in an aluminum foil bag, add desiccant, label (test plate name, batch number, expiration date), seal with a sealer, and store at 4°C for later use. The preparation of the coated plate is complete.
[0177] Combined ELISA experimental steps,
[0178] 1) Return the SASP classical factor-coated plate to room temperature;
[0179] 2) diluting the SASP classical factor antigen according to the following gradient: 200 μg / ml, 100 μg / ml, 50 μg / ml, 25 μg / ml, 12.50 μg / ml, 6.250 μg / ml, 3.1250 μg / ml, 1.560 μg / ml, with the diluent being the sample diluent, to prepare a standard;
[0180] The clinical blood supernatant to be tested is diluted with the above sample diluent to obtain a sample to be tested;
[0181] 3) Add 50 μl / well of diluted standard and sample to each well and incubate at 37°C for 30 min;
[0182] 4) Discard the supernatant, wash the plate 5 times with solid plate washing solution (PBST), and pat dry with absorbent paper;
[0183] 5) Add HRP-SASP classical factor 1:3000 enzyme-labeled antibody, sample volume: 50 μl / well, incubate at 37°C for 30 min;
[0184] 6) Discard the supernatant, wash the plate 5 times with solid plate washing solution (PBST), and pat dry with absorbent paper;
[0185] 7) Add equal volumes of luminescent substrate A + substrate B to each well (100 μl / well), incubate at 37°C for 5 min in the dark, and then place in a luminometer to read the value.
[0186] 8) Perform relative quantification of clinical blood supernatant according to the standard curve and calculate the content of each SASP classical factor.
[0187] 3 Experimental results:
[0188] Luminescence value of the standard without added neutralizing antibody:
[0189] Table 6. Luminescence values of standard products (such as IL6) in comparative example 1
[0190]
[0191]
[0192] The results are shown in the calculation software combined with relevant parameters. Figure 1 .
[0193] Luminescence value after adding neutralizing antibody:
[0194] Table 7. Luminescence values of standard products in Example 1
[0195] Standard + 5μg / ml IL6 neutralizing antibody Luminescence value (OD450) 200 20.1342.3 100 110526.8 50 56043.0 25 39405.2 125 18685.8 625 11659.9 3125 5584.1 15625 2965.8 0 463.5
[0196] By calculating the relevant parameters, the results are shown in Figure 2 .
[0197] Five experimental conclusions:
[0198] 1 Then, through cross-matching, the best reactive and linear pair of human SASP classical factor + HRP-human SASP classical factor enzyme-labeled antibody is selected.
[0199] 2. Screen the coating conditions of ELISA luminescent plate, and finally determine the working concentration of the human SASP classical factor quantitative determination kit: SASP classical factor coating concentration 5μg / ml, SASP classical factor-HRP1:3000;
[0200] 3 Add 5 μg / ml rabbit anti-human SASP classical factor antibody, the correlation is based on the R before addition 2 =0.99985 becomes R 2 =0.99998, detection range is 0-200μg / ml.
[0201] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. Use of a combined ELISA kit as a positive control or a negative control, characterized in that: The combined ELISA kit is pre-packaged with a microplate, a buffer, a blocking solution, a sample diluent, an enzyme diluent, a SASP factor standard, a SASP classical factor antibody, a biological enzyme-labeled SASP classical factor antibody, and a luminescent substrate, wherein the SASP classical factor antibody is a specific polyclonal antibody of the SASP classical exocrine factor of human cells.
2. The use of the combined ELISA kit according to claim 1 as a positive control or a negative control, characterized in that: The preparation process of SASP classical factor antibodies includes: Step 1: Molecularly clone eight human SASP classical factors IL1a, IL1b, IL6, IL8, MMP1, MMP3, GM-CSF, and SPINK1 into the pET-28 fusion protein prokaryotic expression vector (5369 bp); Step 2: Design primers based on the T7 promoter sequence, sequence to determine the MCS segment gene ID, and sequentially transfer the vector into the BL21DE3 competent Escherichia coli strain; Step 3: After inducing the strain to express each target protein, high-purity recombinant protein with a His tag at the N-terminus is obtained by affinity chromatography; Step 4: New Zealand white rabbits are injected with purified proteins in sequence for immunization, and titer detection is performed; samples include pre-immunization negative blood control, first immunization, second immunization, third immunization and fourth immunization gradient titer detection, and the titer detection data are analyzed; the immunization cycle is 2 months; Step 5: Animal serum collection and antibody purification in small amounts; after immunization, serum collection takes place over a 7-12 day period, in batches according to the immunization time; the volume of whole blood collected from each rabbit is no less than 50 ml, and the volume of serum is no less than 30 ml; Step 6: Column purification of polyclonal antibodies: first take a small amount of antibody for purification and identification, and determine the basic purity based on the SDS-PAGE gel image.
3. A method for using a combined ELISA kit for a positive control or a negative control, characterized in that: The method of use uses the combined ELISA kit for use as a positive control or a negative control as claimed in claim 1, and comprises the following steps: S1. Coating the microplate: Mix the SASP classical exocrine factor antibody of the combined ELISA kit with the buffer, add it to the microplate for coating, and then block the microplate with a blocking solution to form a coated plate; S2. Preparation of standards and samples: mixing the SASP classical exocrine factor standard with the sample diluent to prepare an antigen standard; at the same time, mixing the clinical blood supernatant to be tested with the sample diluent to prepare a test solution; S3, incubation and incubation: adding the test solution, antigen standard and SASP classical exocrine factor antibody solution labeled with biological enzyme to the coated plate for incubation, and finally adding the luminescent substrate for incubation; S4, luminescence value detection: Detect the luminescence value of each well by a luminometer; S5. Data analysis: Calculate the content of SASP classical exocrine factors in the sample to be tested according to the standard curve; S6. Use of control substances: Add samples known to contain the target SASP classical factor to the experiment to verify the detection ability of the kit; the positive control substance generates a signal to confirm that the experimental system can detect the target molecule; or: Use sample dilutions without the target SASP classical factor as negative controls to ensure that there is no nonspecific binding or background signal in the experiment.
4. The combined ELISA kit is used to detect the content of SASP classical exocrine factors in a sample, characterized in that: The combined ELISA kit is pre-packaged with a microplate, a buffer, a blocking solution, a sample diluent, an enzyme diluent, a SASP factor standard, a SASP classical factor antibody, a biological enzyme-labeled SASP classical factor antibody, and a luminescent substrate, wherein the SASP classical factor antibody is a specific polyclonal antibody of the SASP classical exocrine factor of human cells.
5. Use of the combined ELISA kit according to claim 4 for detecting the content of SASP classical exocrine factors in a sample, characterized in that: The preparation process of SASP classical factor antibodies includes: Step 1: Molecularly clone eight human SASP classical factors IL1a, IL1b, IL6, IL8, MMP1, MMP3, GM-CSF, and SPINK1 into the pET-28 fusion protein prokaryotic expression vector (5369 bp); Step 2: Design primers based on the T7 promoter sequence, sequence to determine the MCS segment gene ID, and sequentially transfer the vector into the BL21DE3 competent Escherichia coli strain; Step 3: After inducing the strain to express each target protein, high-purity recombinant protein with a His tag at the N-terminus is obtained by affinity chromatography; Step 4: New Zealand white rabbits are injected with purified proteins in sequence for immunization, and titer detection is performed; samples include pre-immunization negative blood control, first immunization, second immunization, third immunization and fourth immunization gradient titer detection, and the titer detection data are analyzed; the immunization cycle is 2 months; Step 5: Animal serum collection and antibody purification in small amounts; after immunization, serum collection takes place over a 7-12 day period, in batches according to the immunization time; the volume of whole blood collected from each rabbit is no less than 50 ml, and the volume of serum is no less than 30 ml; Step 6: Column purification of polyclonal antibodies: first take a small amount of antibody for purification and identification, and determine the basic purity based on the SDS-PAGE gel image.
6. A method for using a combined ELISA kit to detect the content of SASP classical exocrine factors in a sample, characterized in that: The method of use uses the combined ELISA kit for the purpose of detecting the content of SASP classical exocrine factors in a sample as claimed in claim 4, and comprises the following steps: P1. Mix the SASP classical exocrine factor antibodies with the buffer solution one by one, add the obtained antibody solution to the microplate for coating, and then add the blocking solution to the microplate for blocking to obtain a coated plate; P2, mixing the sample to be tested with the sample diluent to prepare a test solution and an antigen standard; P3, mixing the SASP classical exocrine factor standard with the sample diluent to prepare the antigen standard; P4, mixing the SASP classical exocrine factor antibody labeled with biological enzyme with the enzyme diluent to obtain the SASP classical exocrine factor antibody solution labeled with biological enzyme; P5, add the test solution and the antigen standard to the coated plate for incubation, then add the SASP classic exocrine factor antibody solution labeled with a biological enzyme for incubation, and finally add the luminescent substrate for incubation; P6. Detect the luminescence value and obtain the content of SASP classical exocrine factors in the sample to be tested according to the standard curve.
7. The method for using the combined ELISA kit according to claim 6 for detecting the content of SASP classical exocrine factors in a sample, characterized in that: The coating concentration of the SASP classical exocrine factor antibody is 4-10 μg / mL.
8. The method for using the combined ELISA kit according to claim 6 for detecting the content of SASP classical exocrine factors in a sample, characterized in that: In the biological enzyme-labeled SASP classical exocrine factor antibody solution, the volume ratio of the biological enzyme-labeled SASP classical exocrine factor antibody to the enzyme diluent is 1:(2500-3500).
